Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cocrystal Pharma, Inc. Director's Dealing 2021

Jul 20, 2021

35066_dirs_2021-07-20_ded04a35-f122-4a8e-8fd6-baaafed1c37b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2021-07-16

Reporting Person: Lee Sam (President and Co-Interim CEO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-16 Stock Options (Right to Buy) $1.11 A 250000 Acquired 2031-07-16 Common Stock (250000) Direct

Footnotes

F1: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code").

F2: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date.